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ABSTRACT 
Background- Subcutaneous implantable cardioverter defibrillators (S-ICD) have become more 
widely available. However, comparisons with conventional transvenous ICDs (TV-ICD) are 
scarce.   
 
Methods and Results- We conducted a propensity matched case-control study including all 
patients that underwent S-ICD implantation over a five-year period in a single tertiary centre. 
Controls consisted of all TV-ICD implant patients over a contemporary time period excluding 
those with pacing indication, biventricular pacemakers and those with sustained monomorphic 
ventricular tachycardia requiring anti-tachycardia pacing. Data was collected on device-related 
complications and mortality rates. A cost efficacy analysis was performed. Sixty-nine S-ICD 
cases were propensity matched to 69 TV-ICD controls. During a mean follow-up of 31 ± 19 (S-
ICD) and 38 ± 27 months (TV-ICD; p=0.11) there was a higher rate of device-related 
complications in the TV-ICD group predominantly accounted for by lead failures (n=20, 29% vs. 
n=6, 9%; p=0.004). S-ICD was associated with a relative risk reduction of device-related 
complications of 70%. The total mean cost for each group, including the complication-related 
costs was  £9967 ± 4511 ($13,639 ± 6173) and £12601 ± 1786 ($17,243 ± 2444) in the TV-ICD 
and S-ICD groups respectively (p=0.0001). If the annual complication incidence rates remained 
constant in both groups, the cumulative cost would be balanced in five years.  
 
Conclusions- TV-ICDs are associated with increased device-related complication rates 
compared to a propensity matched S-ICD group during a similar follow-up period. Despite the 
existing significant difference in unit cost of the S-ICD, overall S-ICD costs may not exceed TV-
ICD over a longer follow-up period.  
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INTRODUCTION 
The implantable cardioverter defibrillator (ICD) is a well-established treatment for the 
prevention of sudden cardiac death (SCD) (1-3). Over 300, 000 Transvenous ICDs (TV-ICD) are 
implanted worldwide per annum (4). However, these devices have been associated with early 
and long-term complications (5-10). Device-related infection rates of between 0.67-1.49% have 
been reported over a three to 12 month follow-up period (5, 6, 8). Overall pooled complication 
rates secondary mainly to lead displacement, hematoma, pneumothorax (excluding inappropriate 
shocks) of 9%, are reported in randomized controlled trials (11). Long-term lead failure rates of 
up to 20% have been reported over a ten-year period (12). These complications are recognized to 
have a financial impact (13, 14).  
 
Subcutaneous ICDs (S-ICDs) were introduced into clinical practice initially to treat those 
patients where venous access is not feasible due to their underlying anatomy, such as in 
congenital heart disease limiting the introduction of intracardiac leads, and young adults where 
lead longevity and the possible need of lead extraction in the future is a concern (15). 
Preliminary results suggest that these devices are safe and effective (16-18).  
 
As of yet there is minimal data available directly comparing S-ICDs and TV-ICDs in terms of 
complication rates (19, 10). From a cost-efficacy perspective S-ICDs are initially more 
expensive than conventional TV-ICDs at implant. However, the impact of potential differences 
in long-term complication rates on the overall cost has not yet been addressed.  
 
We conducted a propensity matched case (S-ICD)-control (TV-ICD) study with the aims to i) 
compare the safety and efficacy during a long-term follow-up between these two groups ii) 
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perform a cost efficacy analysis evaluating whether the initial implant costs are balanced by the 
long-term economic impact of device-related complications. 
 
METHOD 
Sample Characterization 
We included all patients that underwent S-ICD implantation over a five-year period in a single 
tertiary center. These were defined as the cases. The controls used in the propensity match 
included all patients that underwent TV-ICD implantation over a contemporary period in the 
same centre. Patients who had a concomitant pacing indication, biventricular devices, 
documentation of sustained monomorphic ventricular tachycardia (VT) likely to require anti-
tachycardia pacing (ATP), and advisory transvenous leads were excluded. Using electronic and 
paper records we collected data on baseline characteristics including age, gender, diabetes, 
hypertension, chronic kidney disease (defined as stage 4 or 5), and left ventricular ejection 
fraction (EF). Data was also collected on the underlying cardiac etiology and the indication of 
the ICD implant i.e. primary or secondary prevention. Propensity score matching employing the 
factors in table 1 and with a 1:1 ratio was used to obtain a control group of TV-ICDs and assure 
that S-ICDs and their contemporary controls were similar in all baseline variables. Probabilities 
in the S-ICD group were matched 1:1 to the best TV-ICD corresponding patient.  
 
S-ICD procedure 
Prior to S-ICD implantation all patients undergo electrocardiogram (ECG) screening to ensure 
suitability for a S-ICD through excluding those susceptible to T wave over-sensing. S-ICD 
implantation at our centre is performed under general anesthetic (GA).  
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Device Programming 
TV-ICDs were programmed either with one or two therapy zones based on the patient’s age, 
underlying cardiac etiology and the presence of previous ventricular arrhythmia events. ATP and 
shocks were programmed in the VT and ventricular fibrillation (VF) zone in TV-ICDs. 
Subsequent adjustments to therapies and detection zones were performed during follow-up, or 
following the occurrence of arrhythmic events. Supraventricular tachycardia discriminators were 
switched on and high-rate timeout turned off.  
 
Follow-up and Outcomes 
Data was collected on complication rates during follow-up. This included any early or late 
complications deemed to be related to the device. Early complications were implant-related 
complications i.e. those that occurred within 30 days of the first implant. Device-related 
infections were those necessitating removal of the ICD system and/or antibiotic treatment. 
Pocket hematoma were defined as those resulting in >2g/dl Haemoglobin loss and/or requiring 
evacuation. Lead failure was defined as those that resulted in inappropriate shocks secondary to 
lead noise and/or replacement of the lead. Once a patient experienced a device-related 
complication they were blanked from further analysis therefore follow-up was based on time to 
event.  
 
Data from our local device clinic follow-up records and stored device electrograms (EGMs) 
during episodes of detected VT/VF, any therapy deliveries, and inappropriate shocks were 
analyzed by a cardiac physiologist specializing in Electrophysiology, Consultant 
Electrophysiologist or Senior Electrophysiology Fellow. Sustained VT episodes meeting criteria 
for appropriate ICD intervention were classified as either VT/VF, according to the rate and 
detection window where therapy was delivered. Non-sustained VT episodes that met detection 
 7 
criteria and terminated before therapy was delivered were not classified as VT/VF. Patients were 
classified as having had appropriate shocks, if a shock was delivered during a VT or VF event. 
Effective ATP therapy (for TV-ICDs) was defined as overdrive ventricular pacing able to restore 
sinus rhythm following a VT or VF episode. An appropriate ICD intervention was classified as 
the presence of either an appropriate shock or an effective ATP. 
 
The incidence of inappropriate shocks delivered due to misdetection of tachycardia (either supra-
ventricular tachycardia, sinus tachycardia, atrial fibrillation, T-wave over-sensing, lead noise or 
artifact) was also compared between the two treatment groups.  
 
Data regarding multiple arrhythmia episodes (either in the VT or VF zones), and appropriate 
ICD therapies (ATPs and appropriate shocks) in the same patient were collected, and the mean 
number was compared between the two groups. From 2011 onwards, home-monitoring systems 
(LATITUDE, CARELINK and MERLIN) became available in our Institution and were also used 
for follow-up purposes. 
 
We also collected data on mortality rates in both groups particularly if any deaths were device-
related.   
 
Cost-Efficacy Analysis 
A cost efficacy analysis was performed where the initial implant costs and the costs of device-
related complications in each group were determined and compared. For the device-related 
complications we took into account the costs of repeat procedure(s) including catheterization 
(cath) lab usage, GA cost, procedure-related equipment costs, and the cost of the new implant 
and hospital stay. We also took on board the cost of the investigations performed pre and post 
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their repeat procedure i.e. ECGs, blood tests, blood cultures, chest x-ray, echocardiogram. As the 
mean procedure time and hospital stay for the initial TV-ICD and S-ICD procedure was not 
different in our cohort, the cost related directly to these were not taken into account when 
determining the cost difference between the two groups. As the S-ICDs were implanted under 
GA the cost related to GA was included in the implant cost. The UK Department of Health 
published costs for hospital stay are used by the centre in the costing of hospital stay for each 
patient and were thereby used in our cost calculations (20). The cost of the device and procedure-
related equipment were based on the cost the centre paid directly to the manufacturer to purchase 
the products. The costs of the relevant investigations were obtained from the NICE guidelines on 
preoperative tests (21).  
 
Statistical analysis 
A propensity score was obtained for all eligible participants undergoing ICD implantation 
through binary logistic regression: ICD modality (TV-ICD or S-ICD) was the binary outcome 
and all baseline variables (table 1) were used as covariates for estimating a probability (the 
propensity score). Then, probabilities in the S-ICD group were matched 1:1 to the closest TV-
ICD patient fulfilling inclusion criteria using the nearest neighbor matching approach. The 
propensity score was matched to 5 decimals whenever possible. If this was not possible, we 
subsequently attempted 4, 3 and then 2 decimal matching. If a S-ICD patient could not be 
matched to any TV-ICD subject on the second digit of the propensity score, then the S-ICD 
subject was discarded from the matched analysis. 
 
Comparisons between S-ICD and TV-ICD were performed. Based on Stuart (22), analyses were 
performed using the groups as a whole, rather than using the individual matched pairs. Chi-
square was used for the comparison of nominal variables. The student t-test, or its non-
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parametric equivalent, Mann-Whitney when appropriate, was used for comparison of continuous 
variables; the Levene’s test was used in order to check the homogeneity of variance. Cox 
proportional regression model was used to calculate hazard ratios for each individual device-
related complication. Results with p<0.05 were regarded as significant. 
 
Kaplan-Meier curves were traced for comparing survival free from device-related complications 
among the two treatment groups. For the purpose of time to event analysis only time to first 
event was considered, the patients were censored after their first event. SPSS (IBM SPSS 
Statistics, Version 20 IBM Corp, Armonk, NY, USA) was used for descriptive and inferential 
statistical analysis. 
 
RESULTS 
A total of 69 patients underwent S-ICD implantation between 2010-2015. A total of 429 patients 
underwent TV-ICD implantation over a contemporary time period. Following propensity 
matching 69 of these were matched to the S-ICD group. Baseline characteristics of these two 
groups are demonstrated in table 2.  
 
Device programming 
In the TV-ICD group 22 patients had a single VF zone programmed whilst the remaining 47 
patients had an additional VT therapy zone. On average the VT therapy zone started at 176 ± 14 
beats per min (bpm). S-ICDs were programmed with a SVT discriminator zone at 180-220bpm 
and a VF therapy zone at >220 bpm.  
 
Device therapy 
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In the TV-ICD group five patients had an appropriate ICD therapy (n=4 ICD shocks for VT/VF 
and n=1 ATP for VT). In the TV-ICD group the device failed to cardiovert VT in one patient and 
as a result they were externally cardioverted, followed by having the generator changed to a 
high-energy generator. In the S-ICD group three patients had an appropriate shock for VT/VF. In 
one patient the S-ICD failed to cardiovert VT that then spontaneously terminated. The patient 
had the S-ICD device extracted and had a TV-ICD system implanted.  
 
Device-related complications (table 3 and 4) 
During a mean follow up of 38 ± 27 months there was a total of 20 device-related complications 
in 20 patients, including inappropriate shocks, in the TV-ICD group (29%). Figure 1 shows the 
distribution of the causes for the device-related complications in each group. When excluding 
inappropriate shocks there were a total of 14 device-related complications (20%). The most 
common device-related complications in the TV-ICD group were lead-related affecting six 
patients (9%). Lead-related complications were predominantly due to lead fractures or insulation 
defects (3/6, 50%). Lead-related complications resulted in the ICD lead being explanted and a 
new ICD lead being implanted in five out of the six cases. This was performed under GA in all 
five cases. In the TV-ICD group, one patient also experienced atrial lead displacement within 
two months of implant and required repositioning of the atrial lead. This was not included when 
comparing device-related complications between TV-ICD vs. S-ICDs. During a mean follow-up 
31 ± 19 months there were a total of six device-related complications in the S-ICD group (10%) 
that was predominantly made up of inappropriate shocks (n=3, 4%).  
 
There were two implant-related complications (<30 days) in the TV-ICD group whilst no 
implant-related complications were seen in the S-ICD group. 
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Device-related infections occurred in both groups that required generator and lead extraction and 
implantation of a new system (TV-ICD n=4 vs. S-ICD n=1; p=0.37). There were no associated 
complications from the device extraction.  
A total of six inappropriate shocks occurred in the TV-ICD group versus three in the S-ICD 
group (9% vs. 3%; p=0.49). The reasons for the inappropriate shocks are demonstrated in table 3. 
Three out of the six inappropriate shocks in the TV-ICD group occurred in patients that had two 
therapy zones programmed (3/47 vs. 3/22; p=0.37). Inappropriate shocks in the S-ICD group 
were all due to T wave over-sensing in sinus rhythm and were effectively managed by changing 
the sensing vector.  
 
One of the patients in the TV-ICD group underwent a S-ICD implant following transvenous 
system extraction due to device-related systemic infection. In the S-ICD group one patient had a 
TV-ICD implanted following S-ICD extraction as it failed to cardiovert haemodynamically 
tolerated VT.  
 
When comparing the device-related complications between TV-ICD and S-ICD including 
inappropriate shocks, there were significantly more complications seen in the TV-ICD group 
(n=20, 29% vs. n=6, 9%; p=0.004). This was also the case when excluding all inappropriate 
shocks (n=14, 20% vs. 3, 4%; p=0.008) and excluding inappropriate shocks in those in the TV-
ICD group with two-therapy zone programmed (n=17, 25% vs. n=6, 9%; p=0.021). The S-ICD 
group had a significantly lower risk of device-related complications compared to the TV-ICD 
group (HR 0.30, 95% CI 0.12-0.76; p=0.01).  There was a 70% relative risk reduction (RRR) of 
device-related complications in the S-ICD group compared to the TV-ICD group. The Kaplan 
Meier curves show that in the S-ICD group, there was a higher rate of survival free from device-
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related complications during follow-up (figure 2; HR=2.78; 95%CI 1.10-7.01, P=0.031). There 
were no deaths in either group.  
 
Cost efficacy analysis  
The initial implant costs and the costs related to device complications are demonstrated in table 
5. The mean device-related complication cost was significantly higher in the TV-ICD group 
(£7281 ± 4972 ($9963 ± 6804) TV-ICD vs. £2896 ± 1833 ($3963 ± 2508) S-ICD; p=0.0027). 
The overall mean cost per patient including initial implant and complication costs was £12601 ± 
1786 ($17,243 ± 2444) for S-ICD and £9967 ± 4511 ($13,639 ± 6173) for TV-ICD (p=0.0001). 
Assuming the annual complication incidence rates remained constant in both groups, the 
cumulative cost related to TV-ICDs would be balanced over the next five years (TV-ICD £91774 
($121,252) vs. S-ICD £903125 ($119,3213)) with a possible increased cost of £212 ($279) per 
patient in the TV-ICD group.  
 
DISCUSSION 
This is the first propensity-matched case-control study comparing both complication rates and 
cost between S-ICD and TV-ICD. We conclude that there was a significant increase in device-
related complication in the TV-ICD group compared to the S-ICD group with S-ICDs being 
associated with a 70% RRR in device-related complications.  Furthermore, despite the 
significant difference in unit cost of the S-ICD (i.e. the S-ICD is initially more expensive), the 
overall S-ICD costs tend to balance with those of the TV-ICD over a longer period of follow-up.  
 
In the TV-ICD group the most common complication encountered was lead-related (n=6, 9%) 
and this resulted in the need for lead replacement and removal of the existing lead in majority of 
cases (5/7, 71%), suggesting the ICD lead is truly the Achilles’ heel of the system (23). Further 
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to this, three patients had suspected lead fractures (4.3%). It has been demonstrated that lead 
failure rates are higher in younger patients (24, 25), which correlated with our findings as these 
patients were in the younger age group in our cohort.  
 
The most frequent complication in the S-ICD group was inappropriate shocks due to T wave 
over-sensing in sinus tachycardia. The rates of inappropriate shocks in our cohort was lower than 
that reported in previous studies (4% vs. 7-13%) (17, 18). In all cases of inappropriate shocks we 
were able to prevent any further recurrence through altering the sensing vector. It has been 
shown that patients with TV-ICDs with two therapy zones programmed experience higher rates 
of inappropriate shocks (26-28). However, in our cohort there was no significant difference in 
inappropriate shock rates in those with single or two-therapy zones programmed (p=1.00). The 
inappropriate shock rates in those with single treatment zone programming were similar to that 
of already published data (27, 28). When excluding, from the TV-ICD group those with 
inappropriate shocks and two-therapy zone programming, the device-related complications were 
still significantly higher in the TV-ICD group compared to the S-ICD group (p=0.021).  
 
Device-related complications add an extra £145,609 ($199, 251) to the total cost associated with 
TV-ICDs. Despite this there was an excess cost of £2,634 ($3604) per patient in the S-ICD 
group. However, it can be argued that paying this additional cost to achieve a 70% RRR in 
device-related complications and thereby minimizing patient morbidity is a justified investment. 
Furthermore, the risk of lead failure increases as the transvenous lead ages (24) and therefore it is 
likely that the costs related to complications will increase with time in the TV-ICD group (i.e. it 
is likely that our analysis was a best case scenario for TV-ICDs). If the incidence rate of device-
related complications remains stable over the next five years we would not expect a cost 
difference between these two groups with the further caveat the S-ICD generator change pocket 
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complications such as infection are equivalent to TV-ICD and there are no long-term S-ICD lead 
complications.  
 
In this study we excluded all patients that had any pacing requirement and those with sustained 
monomorphic VT requiring ATP. Further to this, one of the patients in the S-ICD group had 
their system extracted as it failed to terminate ventricular arrhythmia and went on to have a TV-
ICD implanted. In the TV-ICD group one patient had their ICD system extracted due to systemic 
infection and went on to have a S-ICD implanted. This does emphasize the importance of careful 
patient selection in ICD device prescription. 
 
Limitations 
This is a propensity-matched study over a relatively short time frame of around 30 months and 
therefore additional unforeseen events may develop over a longer time frame that could 
influence these findings. The majority of the patients in this cohort had hypertrophic 
cardiomyopathy reflecting the S-ICD population at our centre in the early phases of S-ICD use, 
and therefore the findings may not be transferable to the general ICD population. Every attempt 
was made to match patients with single chamber ICDs, which was achieved in 72% of cases. 
Since only one patient had an atrial lead displacement, the utilization of a dual chamber ICD did 
not significantly affect the findings in terms of lead complications. Costs may vary between 
nations and reimbursement structures but this analysis provides an indication of the relative 
differences between the two devices and could be adjusted accordingly depending on individual 
local reimbursement structures. 
 
CONCLUSION 
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We have demonstrated that the device-related complication rates associated with TV-ICDs are 
higher than that of S-ICDs. We have further shown that there is no significant difference in 
inappropriate shock rates between these two groups. Despite there being a significant difference 
in unit cost of the S-ICD, overall S-ICD costs may not exceed TV-ICD over a longer period of 
follow-up. This will need to be further evaluated in a randomized controlled study.  
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Table 1- Shows the factors that were used in the propensity match  
 
Factors used in the propensity matching  
Age  
Gender 
Diabetes 
Hypertension  
Chronic kidney disease 
Left ventricular ejection fraction 
Cardiac aetiology 
Indication i.e. primary or secondary prevention  
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Table 2- Demonstrates the baseline characteristics of the patients in the S-ICD and TV-ICD group  
 
 
 
Baseline characteristics used in propensity match  S-ICD n=69 TV-ICD n=69 p- value  
Age mean ± SD 35 ±13 40 ±10 0.17 
Male n (%) 52 (75) 52 (75) 1.00 
DM n (%) 0 0 
 Hypertension n (%) 6 (9) 4 (6) 0.74 
CKD n (%) 1 (1) 1 (1) 1.00 
Aetiology n (%) 
         Ischaemic cardiomyopathy 6 (9) 5 (7) 1.00 
      Dilated cardiomyopathy 4 (6) 5 (7) 1.00 
      Hypertrophic cardiomyopathy 41 (59) 42 (61) 1.00 
      Arrhythmogenic right ventricular    
      cardiomyopathy 7 (10) 6 (9) 0.79 
      Idiopathic ventricular fibrillation 6 (9) 6 (9) 1.00 
      Brugada Syndrome 4 (6) 4 (6) 1.00 
      Congenital heart disease 1 (1) 1 (1) 1.00 
Indication n (%) 
         Primary prevention 56 (81) 56 (81) 1.00 
      Secondary prevention  13 (19) 13 (19) 1.00 
Left ventricular ejection fraction mean ± SD 57 (±15) 58 (±13) 0.80 
      EF ≤35 n (%) 12 (17) 7 (10) 0.32 
      EF 36-44 n (%) 1 (1) 5 (7) 0.21 
      EF 45-54 n (%) 4 (6) 3 (4) 1.00 
      EF ≥ 55 n (%) 51 (74) 54 (78) 0.69 
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Table 3- Shows the device-related complications in each group during follow-up  
 
Device related complications during follow-up TV-ICD n=69 S-ICD n=69 p-value 
Mean follow up ± SD 32 ± 21 31 ± 19 ...... 
Total number of complications including inappropriate shocks n (%) 20 (29.0) 6 (8.7) 0.004 
Total number of complication excluding inappropriate shocks n (%) 14 (20.2) 3 (4.3) 0.008 
Total number of complication excluding inappropriate shocks in those with 
two therapy zones programmed n (%) 17 (23.2) 6 (8.7) 0.021 
Implant-related complications (<30 days) n (%) 2 (2.9) 0 0.24 
       Right ventricular lead perforation resulting in tamponade 1 (1.4) 0 1.00 
       Right ventricular lead displacement  1 (1.4) 0 1.00 
Device infection n (%) 4 (5.8) 1 (1.4) 0.37 
       Generator and leads explanted  4 (5.8) 1 (1.4) 0.37 
ICD generator-related complications n (%) 1 (1.4) 1 (1.4) 1.00 
       Generator displacement requiring repositioning 0 1 (1.4) 1.00 
       Wound revision  1 (1.4) 0 1.00 
ICD lead-related complications resulting in lead intervention n (%) 6 (8.7) 0 0.028 
       Drop in RV sensing +/-resulting in T wave oversensing  2 (2.9) 0 0.50 
       Raised RV threshold with suspected micro-displacement  1 (1.4) 0 1.00 
       Lead fracture or lead insulation defect  3 (4.3) 0 0.12 
Device failed to cardiovert ventricular arrhythmia n (%)  1 (1.4) 1 (1.4) 1.00 
       Generator replaced to a high energy box  1 (1.4) 0 1.00 
Inappropriate shocks n (%) 6 (8.7) 3 (4.3) 0.49 
       Sinus tachycardia  2 (2.9) 0 0.50 
       Atrial tachycardia  1 (1.4) 0 1.00 
       Atrial fibrillation  3 (4.3) 0 0.24 
       T wave-oversensing in context of sinus tachycardia  0 3 (4.3) 0.24 
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Table 4- Demonstrates the incidence rate per 100 person-year and hazard ratios in S-ICD and 
TV-ICD groups  
 
           S-ICD n=69         TV-ICD n=69                    HR                   p-value 
Total device-related complications 
excluding implant-related  
     Incidence rate* (95% CI) 
 
      
        45.4 (22.8-70.1) 
        
      
       55.6  (38.8-71.2)   
               
       
          0.30 (0.12-0.76)          0.01 
Device infection 
     Incidence rate* (95% CI) 
         
        48.9 (9.2-90.0) 
     
     74.3 (34.3-94.2) 
 
          0.02 (0-220.24)           0.42 
ICD generator-related complications 
     Incidence rate* (95%CI)  
 
45.5 (8.6-88.2) 
  
    44.1 (8.3-87.4) 
         
                                              0.61 
ICD lead-related complications 
      Incidence rate* (95% CI) 
 
0 
 
      48.8 (24.7-73.5) 
 
                                            N/A 
Device failed to cardiovert 
ventricular arrhythmia  
       Incidence rate* (95% CI) 
 
 
  68.3 (13.3-97.0) 
 
 
      71.0 (13.9-97.4) 
     
 
                                              0.61 
Inappropriate shock 
        Incidence rate* (95% CI)  
 
35.4 (12.5-66.0) 
   
     54.0 (27.7-78.3) 
 
           0.34 (0.07-1.71)         0.19  
 
* Per 100 person-year  
 25 
Table 5- Demonstrates the initial implant costs and the costs associated with the complications 
seen during follow up in each group  
 
               TV-ICD n=69         S-ICD n=69 p-value 
Median hospital stay, days (range) 1 (1-9) 1 (1-9) 1.00 
Total initial implant cost including GA cost £ ($) 542, 085 (741,789) 852,150 (116,6082)  
Total device-related complication costs £ ($) 
     Hospital stay  
     Procedure-related costs*  
     Generator and/or lead replacement  
145,609 (199, 251) 
42,139  (57, 663)   
46,250 (63, 289) 
57,220 (78, 300) 
17,381 (23, 784)  
2181 (2984) 
3200 (4378) 
12,000 (16,421) 
 
 
 
Total overall cost £ ($) 687, 694 (941, 040) 869, 531 (118,9866)  
Mean cost of a device-related complication £ ($) 
Mean cost per patient £ ($) 
7281 ± 4972 (9963 ± 6804) 
9967 ± 4511 
(13,639 ± 6173) 
2896 ± 1833 (3963 ± 2508) 
12,601 ± 1786 
(17,243 ± 2444) 
    0.0027 
  0.0001 
 
* Including pre and post procedural investigations, cath lab time, GA and equipment costs 
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FIGURE LEGEND 
Figure 1- Pie charts demonstrating the device-related complications seen in the S-ICD and TV-
ICD group during follow-up. 
 
Figure 2- Kaplan Meier survival curves demonstrating the survival free from device-related 
complications in the S-ICD and TV-ICD group.  
 
 
 
 
 
